According to the service provider, the acquisition increases its disease-state biospecimen capabilities, specifically in oncology.
Asterand Bioscience has offices in Detroit, MI and Royston, UK and provides well-characterized human tissue and research solutions.
“As this is a growing area of the BioreclamationIVT business, we were eager to expand our product portfolio through this acquisition,” Courtney Noah, Ph.D., vice president of marketing at BioreclamationIVT told Outsourcing-Pharma.com.
“This expansion will allow us to better meet the needs of our clients focused on oncology and precision medicine research,” she added.
As for how the companies will be integrated, Noah said, “We will be working closely with the Asterand team over the coming months to align their processes and systems with our existing disease state and service business units.”
According to the company, its new offerings will include target and biomarker validation using histology and molecular techniques, and compound evaluation using cell-based model systems.
The acquisition follows BioreclamationIVT’s purchase of TransCell Science, a privately held contract research organization (CRO) specializing in the use of primary cells for phenotypic screening assays.
BioreclamationIVT acquired TransCell Science in March of this year.
At the time of the acquisition, Jeff Gatz, BioreclamationIVT CEO said: "We expect the expansion of our service offerings will help to speed up the drug discovery process and ensure efficacious therapeutics get to patients that need them most."